DPP4 and cardiomyopathy: Furthermore, the cardioprotective actions of GLP-1(9-36) suggests additional benefits of GLP-1 analogues, which do not interfere with the physiological GLP-1 degradation, over the ones from DPP-IV inhibitors in diabetic and, interestingly, non-diabetic cardiomyopathies.